You are here:
NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Allergies
Omalizumab for treating severe persistent allergic asthma
Technology appraisal guidance
Reference number:
TA278
Published:
24 April 2013
Guidance
Tools and resources
Information for the public
Evidence
History
Download guidance (PDF)
Overview
1 Guidance
2 Clinical need and practice
3 The technology
4 Evidence and interpretation
5 Implementation
6 Related NICE guidance
7 Review of guidance
Appendix A: Appraisal Committee members and NICE project team
Appendix B: Sources of evidence considered by the Committee
Changes after publication
About this guidance
Changes after publication
January 2014:
minor maintenance.
Next page
About this guidance
Previous page
Appendix B: Sources of evidence considered by the Committee